Greenwich Lifesciences Inc (GLSI) - Total Assets
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) holds total assets worth $3.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Greenwich Lifesciences Inc (GLSI) shareholders funds for net asset value and shareholders' equity analysis.
Greenwich Lifesciences Inc - Total Assets Trend (2017–2024)
This chart illustrates how Greenwich Lifesciences Inc's total assets have evolved over time, based on quarterly financial data.
Greenwich Lifesciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Greenwich Lifesciences Inc's total assets of $3.81 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.78K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Greenwich Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Greenwich Lifesciences Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Greenwich Lifesciences Inc's current assets represent 100.0% of total assets in 2024, an increase from 0.2% in 2017.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2024, up from 0.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
Greenwich Lifesciences Inc Competitors by Total Assets
Key competitors of Greenwich Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Greenwich Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.35 | 6.91 | 27.41 |
| Quick Ratio | 2.35 | 6.91 | 27.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.18 Million | $4.98 Million | $27.61 Million |
Greenwich Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between Greenwich Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 146.16 |
| Latest Market Cap to Assets Ratio | 78.14 |
| Asset Growth Rate (YoY) | -41.5% |
| Total Assets | $4.09 Million |
| Market Capitalization | $319.90 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Greenwich Lifesciences Inc's assets at a significant premium (78.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Greenwich Lifesciences Inc's assets decreased by 41.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Greenwich Lifesciences Inc (2017–2024)
The table below shows the annual total assets of Greenwich Lifesciences Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.09 Million | -41.47% |
| 2023-12-31 | $6.99 Million | -48.10% |
| 2022-12-31 | $13.48 Million | -50.48% |
| 2021-12-31 | $27.22 Million | -5.09% |
| 2020-12-31 | $28.68 Million | +107419.79% |
| 2019-12-31 | $26.67K | -75.43% |
| 2018-12-31 | $108.55K | +300.48% |
| 2017-12-31 | $27.10K | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also de… Read more